An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site

Vaccine

Volumn 30, Issue 5, 2012, Pages 922-930

  Ahmed, Fatima K ^a   Clark, Brenda E ^a,d   Burton, Dennis R ^b,c   Pantophlet, Ralph ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d STEMCELL Technologies   (Canada)

Author keywords

B12; Hyperglycosylation; Immunofocusing; Protein engineering

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY B13; MONOCLONAL ANTIBODY VRCO3; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; QUIL A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HYPERGLYCOSYLATION; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; BINDING SITES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; LIPID A; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SAPONINS; VACCINES, SYNTHETIC;

EID: 84855433610     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.089     Document Type: Article

References (82)

1. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
2. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus Type-1 by vaccination. Immunity 2010, 33:542-554.
3. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine. Nat Med 2009, 15:866-870.
4. Verkoczy L., Kelsoe G., Moody M.A., Haynes B.F. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2011, 23:383-390.
5. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
6. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
7. Corti D., Langedijk J.P.M., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
8. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007, 13:1032-1034.
9. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
10. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:757-769.
11. Sather D.N., Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010, 28:B8-B12.
12. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010, 6:e1001028.
13. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007, 81:6548-6562.
14. Tomaras G.D., Binley J.M., Gray E.S., Crooks E.T., Osawa K., Moore P.L., et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1- infected individuals. J Virol 2011, 85:11502-11519.
15. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Olivera T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 16:1633-1637.
16. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
17. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
18. Gray E.S., Taylor N., Wycuff D., Moore P.L., Tomaras G.D., Wibmer C.K., et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009, 83:8925-8937.
19. Nandi A., Lavine C.L., Wang P., Lipchina I., Goepfert P.A., Shaw G.M., et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 2010, 396:339-348.
20. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15:951-954.
21. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
22. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001, 75:8340-8347.
23. Burton D.R., Hessell A.J., Keele B.F., Klasse P.J., Ketas T.A., Moldt B., et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 2011, 108:11181-11186.
24. Ng C.T., Jaworski J.P., Jayaraman P., Sutton W.F., Delio P., Kuller L., et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010, 16:1117-1119.
25. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
26. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 29:811-817.
27. Chen L., Do Kwon Y., Zhou T., Wu X., O'Dell S., Cavacini L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
28. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003, 77:642-658.
29. Zwick M.B., Parren P.W., Saphire E.O., Church S., Wang M., Scott J.K., et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 2003, 77:5863-5876.
30. Wu X., Zhou T., O'Dell S., Wyatt R.T., Kwong P.D., Mascola J.R. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody b12 that effectively targets the site of CD4 attachment. J Virol 2009, 83:10892-10907.
31. Klein J.S., Gnanapragasam P.N.P., Galimidi R.P., Foglesong C.P., West A.P., Bjorkman P.J. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 2009, 106:7385-7390.
32. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
33. Phogat S., Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des 2007, 13:213-227.
34. Dosenovic P., Chakrabarti B., Soldemo M., Douagi I., Forsell M.N., Li Y., et al. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol 2009, 183:3373-3382.
35. Douagi I., Forsell M.N.E., Sundling C., O'Dell S., Feng Y., Dosenovic P., et al. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 2010, 84:1683-1695.
36. Sundling C., Forsell M.N.E., O'Dell S., Feng Y., Chakrabarti B., Rao S.S., et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010, 207:2003-2017.
37. Wu L., Zhou T., Yang Z-y Svehla K., O'Dell S., Louder M.K., et al. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol 2009, 83:5077-5086.
38. Pantophlet R., Wilson I.A., Burton D.R. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003, 77:5889-5901.
39. Bhattacharyya S., Rajan R.E., Swarupa Y., Rathore U., Verma A., Udaykumar R., et al. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to cd4 and induces neutralizing antibodies. J Biol Chem 2010, 285:27100-27110.
40. Pantophlet R., Wilson I.A., Burton D.R. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng Des Sel 2004, 17:749-758.
41. Pietzsch J., Scheid J.F., Mouquet H., Klein F., Seaman M.S., Jankovic M., et al. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med 2010, 207:1995-2002.
42. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J Virol 2005, 79:12148-12163.
43. Delves P.J., Lund T., Roitt I.M. Can epitope-focused vaccines select advantageous immune responses. Mol Med Today 1997, 3:55-60.
44. Garrity R.R., Rimmelzwaan G., Minassian A., Tsai W.P., Lin G., de Jong J.J., et al. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 1997, 159:279-289.
45. Tobin G.J., Trujillo J.D., Bushnell R.V., Lin G., Chaudhuri A.R., Long J., et al. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008, 26:6189-6199.
46. Nara P.L., Tobin G.J., Chaudhuri A.R., Trujillo J.D., Lin G., Cho M.W., et al. How can vaccines against influenza and other viral diseases be made more effective?. PLoS Biol 2010, 8:e1000571.
47. Dey A.K., Srivastava I.K. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines 2011, 10:227-251.
48. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
49. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29:3341-3355.
50. Coller B.-A.G., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29:7267-7275.
51. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26:2521-2527.
52. Mullen G.E., Aebig J.A., Dobrescu G., Rausch K., Lambert L., Long C.A., et al. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 2007, 25:5343-5347.
53. Aebig J.A., Mullen G.E., Dobrescu G., Rausch K., Lambert L., Ajose-Popoola O., et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007, 323:139-146.
54. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., et al. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 2008, 375:969-978.
55. Zwick M.B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D.R., et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001, 75:12198-12208.
56. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
57. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
58. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
59. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2:219-229.
60. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996, 13:1-55.
61. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1796.
62. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70:1863-1872.
63. Sundling C., Li Y., Huynh N., Wilson R., O'Dell S., Mascola J., et al. Abstract OA04.04 - characterization of CD4-binding site directed monoclonal antibodies isolated from HIV-1 gp140 Env immunized rhesus macaques. Abstracts from AIDS Vaccine 2011 Bangkok, Thailand, 12-15 September, 2011. AIDS Res Hum Retroviruses 2011, 27:A-1-A-148.
64. Schroeder J.H.W. Similarity and divergence in the development and expression of the mouse and human antibody repertoires. Dev Comp Immunol 2006, 30:119-135.
65. Collis A.V.J., Brouwer A.P., Martin A.C.R. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 2003, 325:337-354.
66. Zemlin M., Klinger M., Link J., Zemlin C., Bauer K., Engler J.A., et al. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 2003, 334:733-749.
67. Breden F., Lepik C., Longo N.S., Montero M., Lipsky P.E., Scott J.K. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011, 6:e16857.
68. Popkov M., Mage R.G., Alexander C.B., Thundivalappil S., Barbas C.F., Rader C. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 2003, 325:325-335.
69. Mage R.G., Lanning D., Knight K.L. B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev Comp Immunol 2006, 30:137-153.
70. Mehr R., Edelman H., Sehgal D., Mage R. Analysis of mutational lineage trees from sites of primary and secondary Ig gene diversification in rabbits and chickens. J Immunol 2004, 172:4790-4796.
71. Dennis Lanning X.Z., Zhai S.-K., Katherine L.K. Development of the antibody repertoire in rabbit: gut-associated lymphoid tissue, microbes, and selection. Immunol Rev 2000, 175:214-228.
72. Yuan T., Li J., Zhang Y., Wang Y., Streaker E., Dimitrov D.S., et al. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development. Vaccine 2011, 29:6903-6910.
73. Link J.M., Larson J.E., Schroeder H.W. Despite extensive similarity in germline DH and JH sequence, the adult Rhesus macaque CDR-H3 repertoire differs from human. Mol Immunol 2005, 42:943-955.
74. Li Y., Svehla K., Mathy N.L., Voss G., Mascola J.R., Wyatt R. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006, 80:1414-1426.
75. Kong L., Sheppard N.C., Stewart-Jones G.B., Robson C.L., Chen H., Xu X., et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol 2010, 403:131-147.
76. Grundner C., Pancera M., Kang J.M., Koch M., Sodroski J., Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 2004, 330:233-248.
77. Raska M., Takahashi K., Czernekova L., Zachova K., Hall S., Moldoveanu Z., et al. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 2010, 285:20860-20869.
78. Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 2010, 107:13800-13805.
79. Ofek G., Guenaga F.J., Schief W.R., Skinner J., Baker D., Wyatt R., et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 2010, 107:17880-17887.
80. Guenaga J., Dosenovic P., Ofek G., Baker D., Schief W.R., Kwong P.D., et al. Heterologous epitope-scaffold prime-boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 2011, 6:e16074.
81. Montefiori D. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current protocol in immunology 2004, 12.1.1-12.1.5. John Wiley & Sons, New York. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
82. Hosoi S., Borsos T., Dunlop N., Heat-Labile N.P.L. Complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. J Acquir Immune Defic Syndr 1990, 3:366-371.